At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
We are a network of full-service medical equipment companies that use tailored pro...
We are a network of full-service medical equipm...
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Join the National Investor Network and get the latest information with your interests in mind.